Base de dados : MEDLINE
Pesquisa : D02.241.081.114.625 [Categoria DeCS]
Referências encontradas : 571 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 58 ir para página                         

  1 / 571 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29193021
[Au] Autor:Flinn IW; Thompson DS; Boccia RV; Miletello G; Lipman A; Flora D; Cuevas D; Papish SW; Berdeja JG
[Ad] Endereço:Sarah Cannon Research Institute/Tennessee Oncology PLLC, Nashville, TN, USA.
[Ti] Título:Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma.
[So] Source:Br J Haematol;180(3):365-373, 2018 02.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This Phase II trial evaluated the efficacy of bendamustine, bortezomib and rituximab in patients with previously untreated low-grade lymphoma. Eligible patients had low grade lymphoma with no previous systemic disease treatment. Treatment for all patients was given in 28-day cycles for a maximum of 6 cycles. Patients received rituximab 375 mg/m intravenously (IV) on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2-6; bendamustine 90 mg/m IV on days 1 and 2; and bortezomib 1·6 mg/m IV on days 1, 8 and 15. Patients were permitted to begin maintenance treatment with rituximab 6 months after completion of study treatment and after 6-month follow-up assessments had been conducted. Fifty-four eligible patients were enrolled. The most common grade 3/4 toxicities were leucopenia (28%), neutropenia (30%) and lymphopenia (17%). There were no treatment-related deaths and 1 unrelated death on study (embolic stroke). The overall response rate was 94% for all patients. The median follow-up was 54 months. Kaplan-Meier estimates of progression-free survival and overall survival at 36 months were 75% and 88%, respectively. The treatment regimen was well tolerated and produced high response rates. Further study of this regimen in patients with previously untreated lymphoma is warranted.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Linfoma/tratamento farmacológico
Linfoma/patologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Cloridrato de Bendamustina/administração & dosagem
Bortezomib/administração & dosagem
Feminino
Seres Humanos
Linfoma/mortalidade
Masculino
Meia-Idade
Gradação de Tumores
Estadiamento de Neoplasias
Indução de Remissão
Rituximab/administração & dosagem
Análise de Sobrevida
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; MULTICENTER STUDY; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
4F4X42SYQ6 (Rituximab); 69G8BD63PP (Bortezomib); 981Y8SX18M (Bendamustine Hydrochloride)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171202
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.15044


  2 / 571 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28664772
[Au] Autor:Gordon MJ; Lewis LD; Brown JR; Danilov AV
[Ad] Endereço:a Department of Internal Medicine , Oregon Health & Science University , Portland , OR , USA.
[Ti] Título:Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?
[So] Source:Expert Rev Hematol;10(8):707-718, 2017 Aug.
[Is] ISSN:1747-4094
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The majority of patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) present with comorbidities. Many of them are poor candidates for intensive chemo-immunotherapy regimens, such as FCR (fludarabine, cyclophosphamide, rituximab). Still, most clinical trials aim to enroll 'fit' patients, who poorly represent the community oncology population. Areas covered: In the past decade, bendamustine hydrochloride, a cytotoxic agent with structural similarities to both alkylating agents and purine analogs, has received widespread use in therapy of NHL and CLL, and has demonstrated a relatively favorable toxicity profile. However, bendamustine has not been well studied in patients with hematologic malignancies who have comorbidities. Here we review the clinical data on use of bendamustine in older and unfit patients with NHL and CLL, and analyze whether there is an optimal dose of bendamustine in patients who have significant comorbidities, including renal dysfunction. Expert commentary: Reduced intensity regimens of bendamustine are effective in CLL patients with comorbidities and renal dysfunction. Even with the introduction of targeted therapies, bendamustine will likely continue to be an important therapeutic option in patients with comorbidities because of its tolerability, efficacy and cost.
[Mh] Termos MeSH primário: Antineoplásicos Alquilantes/uso terapêutico
Cloridrato de Bendamustina/uso terapêutico
Leucemia de Células B/tratamento farmacológico
Linfoma de Células B/tratamento farmacológico
[Mh] Termos MeSH secundário: Antineoplásicos Alquilantes/farmacologia
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Cloridrato de Bendamustina/farmacologia
Ensaios Clínicos como Assunto
Comorbidade
Seres Humanos
Leucemia de Células B/diagnóstico
Leucemia de Células B/mortalidade
Leucemia Linfocítica Crônica de Células B/diagnóstico
Leucemia Linfocítica Crônica de Células B/tratamento farmacológico
Leucemia Linfocítica Crônica de Células B/mortalidade
Linfoma de Células B/diagnóstico
Linfoma de Células B/mortalidade
Linfoma não Hodgkin/diagnóstico
Linfoma não Hodgkin/tratamento farmacológico
Linfoma não Hodgkin/mortalidade
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents, Alkylating); 981Y8SX18M (Bendamustine Hydrochloride)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171009
[Lr] Data última revisão:
171009
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170701
[St] Status:MEDLINE
[do] DOI:10.1080/17474086.2017.1350166


  3 / 571 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28620927
[Au] Autor:Bétrian S; Guenounou S; Luquet I; Demur C; Huynh A; Ysebaert L; Recher C; Huguet F
[Ad] Endereço:Hematology Department, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.
[Ti] Título:Bendamustine for relapsed blastic plasmacytoid dendritic cell leukaemia.
[So] Source:Hematol Oncol;35(2):252-255, 2017 Jun.
[Is] ISSN:1099-1069
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Optimal treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare entity of dismal prognosis previously described as CD4+/CD56+ hematodermic malignancies, is not defined. We report five cases of relapsed BPDCN treated with bendamustine hydrochloride, a well-tolerated bifunctional drug acting as an alkylating and antimetabolite agent. All patients were above the age of 50 years and in advanced disease (early first relapse in two, subsequent relapse in three; multi-organ involvement in four; previous intensive chemotherapy in five; and stem cell transplantation in four). Four patients were evaluable for response. Two failed therapy, one died from tumor lysis syndrome after rapid blast clearance from blood, and one reached and maintained complete remission for 7 months. Bendamustine should be further evaluated in BPDCN. Copyright © 2015 John Wiley & Sons, Ltd.
[Mh] Termos MeSH primário: Antineoplásicos Alquilantes/uso terapêutico
Cloridrato de Bendamustina/uso terapêutico
Células Dendríticas/patologia
Neoplasias Hematológicas/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Crise Blástica
Neoplasias Hematológicas/patologia
Seres Humanos
Masculino
Meia-Idade
Recidiva
[Pt] Tipo de publicação:CASE REPORTS
[Nm] Nome de substância:
0 (Antineoplastic Agents, Alkylating); 981Y8SX18M (Bendamustine Hydrochloride)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170830
[Lr] Data última revisão:
170830
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170617
[St] Status:MEDLINE
[do] DOI:10.1002/hon.2252


  4 / 571 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28533306
[Au] Autor:Berentsen S; Randen U; Oksman M; Birgens H; Tvedt THA; Dalgaard J; Galteland E; Haukås E; Brudevold R; Sørbø JH; Næss IA; Malecka A; Tjønnfjord GE
[Ad] Endereço:Department of Research and Innovation, Haugesund Hospital, Haugesund, Norway.
[Ti] Título:Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial.
[So] Source:Blood;130(4):537-541, 2017 Jul 27.
[Is] ISSN:1528-0020
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Primary chronic cold agglutinin disease (CAD) is a well-defined clinicopathologic entity in which a bone marrow clonal B-cell lymphoproliferation results in autoimmune hemolytic anemia and cold-induced circulatory symptoms. Rituximab monotherapy and fludarabine-rituximab in combination are documented treatment options. In a prospective, nonrandomized multicenter trial, 45 eligible patients received rituximab 375 mg/m day 1 and bendamustine 90 mg/m days 1 and 2 for 4 cycles at a 28-day interval. Thirty-two patients (71%) responded; 18 (40%) achieved complete response (CR) and 14 (31%) partial response (PR). Among 14 patients previously treated with rituximab or fludarabine-rituximab, 7 (50%) responded to bendamustine-rituximab (3 CR and 4 PR). Hemoglobin levels increased by a median of 4.4 g/dL in the complete responders, 3.9 g/dL in those achieving PR, and 3.7 g/dL in the whole cohort. The 10th percentile of response duration was not reached after 32 months. Grade 3-4 neutropenia occurred in 15 patients (33%), but only 5 (11%) experienced infection with or without neutropenia. Thirteen patients (29%) had their dose of bendamustine reduced. In conclusion, bendamustine-rituximab combination therapy is highly efficient, sufficiently safe, and may be considered in first line for patients with CAD requiring therapy. The trial was registered at www.clinicaltrials.gov as #NCT02689986.
[Mh] Termos MeSH primário: Anemia Hemolítica Autoimune/tratamento farmacológico
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Anemia Hemolítica Autoimune/sangue
Cloridrato de Bendamustina/administração & dosagem
Doença Crônica
Europa (Continente)
Feminino
Hemoglobinas/metabolismo
Seres Humanos
Masculino
Meia-Idade
Estudos Prospectivos
Rituximab/administração & dosagem
Vidarabina/administração & dosagem
Vidarabina/análogos & derivados
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Hemoglobins); 4F4X42SYQ6 (Rituximab); 981Y8SX18M (Bendamustine Hydrochloride); FA2DM6879K (Vidarabine); P2K93U8740 (fludarabine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170524
[St] Status:MEDLINE
[do] DOI:10.1182/blood-2017-04-778175


  5 / 571 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28419413
[Au] Autor:Martin P; Chen Z; Cheson BD; Robinson KS; Williams M; Rajguru SA; Friedberg JW; van der Jagt RH; LaCasce AS; Joyce R; Ganjoo KN; Bartlett NL; Lemieux B; VanderWalde A; Herst J; Szer J; Bar MH; Cabanillas F; Dodds AJ; Montgomery PG; Pressnail B; Ellis T; Smith MR; Leonard JP
[Ad] Endereço:Weill Cornell Medicine, New York, NY, USA.
[Ti] Título:Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
[So] Source:Br J Haematol;178(2):250-256, 2017 Jul.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Despite the long history of bendamustine as treatment for indolent non-Hodgkin lymphoma, long-term efficacy and toxicity data are minimal. We reviewed long-term data from three clinical trials to characterize the toxicity and efficacy of patients receiving bendamustine. Data were available for 149 subjects at 21 sites. The median age was 60 years at the start of bendamustine (range 39-84), and patients had received a median of 3 prior therapies. The histologies included grades 1-2 follicular lymphoma (FL; n = 73), grade 3 FL (n = 23), small lymphocytic lymphoma (n = 20), marginal zone lymphoma (n = 15), mantle cell lymphoma (n = 9), transformed lymphomas (n = 5), lymphoplasmacytic lymphoma (n = 2) and not reported (n = 2). The median event-free survival was 14·1 months. Nine of 12 attempted stem cell collections were successful. With a median follow-up of 8·9 years, 23 patients developed 25 cancers, including 8 patients with myelodysplastic syndrome/acute myeloid leukaemia. These data provide important information regarding the long-term toxicity of bendamustine in previously treated patients. A small but meaningful number of patients achieved durable remissions following bendamustine. These rigorously collected, patient-level, long-term follow-up data provide reassurance that bendamustine or bendamustine plus rituximab is associated with efficacy and safety for patients with relapsed or refractory indolent non-Hodgkin lymphoma.
[Mh] Termos MeSH primário: Antineoplásicos Alquilantes/administração & dosagem
Cloridrato de Bendamustina/administração & dosagem
Mobilização de Células-Tronco Hematopoéticas/métodos
Linfoma não Hodgkin/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Antineoplásicos Alquilantes/efeitos adversos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Cloridrato de Bendamustina/efeitos adversos
Ensaios Clínicos como Assunto
Intervalo Livre de Doença
Feminino
Seres Humanos
Leucemia Mieloide Aguda/induzido quimicamente
Masculino
Meia-Idade
Estudos Multicêntricos como Assunto
Síndromes Mielodisplásicas/induzido quimicamente
Segunda Neoplasia Primária/induzido quimicamente
Rituximab/administração & dosagem
Rituximab/efeitos adversos
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Antineoplastic Agents, Alkylating); 4F4X42SYQ6 (Rituximab); 981Y8SX18M (Bendamustine Hydrochloride)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170419
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.14667


  6 / 571 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28402581
[Au] Autor:Larsen JT; Shanafelt TD; Leis JF; LaPlant B; Call T; Pettinger A; Hanson C; Erlichman C; Habermann TM; Reeder C; Nikcevich D; Bowen D; Conte M; Boysen J; Secreto C; Lesnick C; Tschumper R; Jelinek D; Kay NE; Ding W
[Ad] Endereço:Division of Hematology, Mayo Clinic, Rochester, Minnesota.
[Ti] Título:Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study.
[So] Source:Am J Hematol;92(8):759-763, 2017 Aug.
[Is] ISSN:1096-8652
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Akt is a downstream target of B cell receptor signaling and is a central regulator of CLL cell survival. We aim to investigate the safety and efficacy of the Akt inhibitor MK-2206 in combination with bendamustine and rituximab (BR) in relapsed and/or refractory CLL in a phase I/II study. A standard phase I design was used with cohorts of three plus three patients to determine the maximum tolerated dose (MTD) of MK-2206 in combination with BR in relapsed CLL. Single-agent MK-2206 (weekly dosed) was administered one-week in advance before BR on cycle 1 and subsequently was given with BR at the same time for cycle 2-6. Phase II employed the MTD of MK-2206 with BR to evaluate safety and efficacy of this study combination. Thirteen relapsed/refractory CLL were treated for maximal 6-cycle of therapy. The maximum tolerated dose of MK-2206 was 90 mg by mouth once weekly. The most common grade 3/4 adverse events were neutropenia (46%), febrile neutropenia (23%), rash (15%), diarrhea (15%), and thrombocytopenia (15%). Overall response rate was 92% with a median progression free survival and treatment free survival of 16 and 24 months, respectively. Five patients (38%) achieved complete remission or complete remission with incomplete count recovery, two of whom were MRD negative. The efficacy and tolerability of this combination indicates that Akt inhibition combined with chemoimmunotherapy is a promising novel treatment combination in CLL and deserves further prospective clinical trial.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Resistência a Medicamentos Antineoplásicos
Leucemia Linfocítica Crônica de Células B/tratamento farmacológico
Leucemia Linfocítica Crônica de Células B/patologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Cloridrato de Bendamustina/administração & dosagem
Feminino
Seguimentos
Compostos Heterocíclicos com 3 Anéis/administração & dosagem
Seres Humanos
Leucemia Linfocítica Crônica de Células B/mortalidade
Masculino
Meia-Idade
Estadiamento de Neoplasias
Recidiva
Retratamento
Rituximab/administração & dosagem
Análise de Sobrevida
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Heterocyclic Compounds, 3-Ring); 0 (MK 2206); 4F4X42SYQ6 (Rituximab); 981Y8SX18M (Bendamustine Hydrochloride)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170728
[Lr] Data última revisão:
170728
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170413
[St] Status:MEDLINE
[do] DOI:10.1002/ajh.24762


  7 / 571 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28395515
[Au] Autor:Martin P; Barr PM; James L; Pathak A; Kahl B
[Ad] Endereço:a Division of Hematology/Oncology , New York-Presbyterian/Weill Cornell Medicine , New York , NY , USA.
[Ti] Título:Long-term safety experience with bendamustine for injection in a real-world setting.
[So] Source:Expert Opin Drug Saf;16(6):647-650, 2017 Jun.
[Is] ISSN:1744-764X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Bendamustine hydrochloride (bendamustine) was approved for first-line treatment of patients with chronic lymphocytic leukemia (CLL) and relapsed indolent B-cell non-Hodgkin's lymphoma (NHL). Pharmacovigilance data have been collected since bendamustine's approval to enhance understanding of its long-term safety profile. Here we provide an overview of the pharmacovigilance data for bendamustine that have led to label updates related to safety and administration since its approval. RESEARCH DESIGN AND METHODS: Adverse events (AEs) captured from 12 quarterly postmarketing periodic adverse drug experience reports spanning 2008-2015 were included and summarized. AEs were classified as serious or nonserious and expected or unexpected. RESULTS: Adverse events that resulted in label updates included Stevens-Johnson syndrome, toxic epidermal necrolysis, extravasation, secondary neoplasm, and drug reactions with eosinophilia and systemic symptoms. Preventive measures for tumor lysis syndrome were revised. Although this review may be limited by voluntary reporting, the adverse events reported for bendamustine in a large, heterogeneous population with a long follow-up relative to recently approved treatments provide a much broader understanding of its safety profile. CONCLUSIONS: Based on these observational data, bendamustine appears to have a favorable risk-benefit profile and remains a useful option when considering a management strategy in patients with CLL and NHL.
[Mh] Termos MeSH primário: Antineoplásicos Alquilantes/administração & dosagem
Cloridrato de Bendamustina/efeitos adversos
Leucemia Linfocítica Crônica de Células B/tratamento farmacológico
Linfoma de Células B/tratamento farmacológico
[Mh] Termos MeSH secundário: Sistemas de Notificação de Reações Adversas a Medicamentos
Antineoplásicos Alquilantes/efeitos adversos
Cloridrato de Bendamustina/administração & dosagem
Seres Humanos
Farmacovigilância
Vigilância de Produtos Comercializados
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents, Alkylating); 981Y8SX18M (Bendamustine Hydrochloride)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170608
[Lr] Data última revisão:
170608
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170412
[St] Status:MEDLINE
[do] DOI:10.1080/14740338.2017.1318125


  8 / 571 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28352172
[Au] Autor:Bhandari J; Mishra H; Mishra PK; Wimmer R; Ahmad FJ; Talegaonkar S
[Ad] Endereço:Department of Pharmaceutics, Jamia Hamdard, New Delhi, India.
[Ti] Título:Cellulose nanofiber aerogel as a promising biomaterial for customized oral drug delivery.
[So] Source:Int J Nanomedicine;12:2021-2031, 2017.
[Is] ISSN:1178-2013
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:Cellulose nanofiber (CNF) aerogels with favorable floatability and mucoadhesive properties prepared by the freeze-drying method have been introduced as new possible carriers for oral controlled drug delivery system. Bendamustine hydrochloride is considered as the model drug. Drug loading was carried out by the physical adsorption method, and optimization of drug-loaded formulation was done using central composite design. A very lightweight-aerogel-with-matrix system was produced with drug loading of 18.98%±1.57%. The produced aerogel was characterized for morphology, tensile strength, swelling tendency in media with different pH values, floating behavior, mucoadhesive detachment force and drug release profiles under different pH conditions. The results showed that the type of matrix was porous and woven with excellent mechanical properties. The drug release was assessed by dialysis, which was fitted with suitable mathematical models. Approximately 69.205%±2.5% of the drug was released in 24 hours in medium of pH 1.2, whereas ~78%±2.28% of drug was released in medium of pH 7.4, with floating behavior for ~7.5 hours. The results of in vivo study showed a 3.25-fold increase in bioavailability. Thus, we concluded that CNF aerogels offer a great possibility for a gastroretentive drug delivery system with improved bioavailability.
[Mh] Termos MeSH primário: Celulose/química
Portadores de Fármacos/administração & dosagem
Portadores de Fármacos/química
Nanofibras/química
[Mh] Termos MeSH secundário: Administração Oral
Animais
Cloridrato de Bendamustina/administração & dosagem
Cloridrato de Bendamustina/química
Cloridrato de Bendamustina/farmacocinética
Materiais Biocompatíveis
Disponibilidade Biológica
Diálise
Portadores de Fármacos/farmacocinética
Sistemas de Liberação de Medicamentos/métodos
Liberação Controlada de Fármacos
Feminino
Liofilização
Concentração de Íons de Hidrogênio
Masculino
Ratos Wistar
Resistência à Tração
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biocompatible Materials); 0 (Drug Carriers); 9004-34-6 (Cellulose); 981Y8SX18M (Bendamustine Hydrochloride)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170530
[Lr] Data última revisão:
170530
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170330
[St] Status:MEDLINE
[do] DOI:10.2147/IJN.S124318


  9 / 571 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28187444
[Au] Autor:Modi P; Balakrishnan K; Yang Q; Wierda WG; Keating MJ; Gandhi V
[Ad] Endereço:Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
[Ti] Título:Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.
[So] Source:Oncotarget;8(10):16259-16274, 2017 Mar 07.
[Is] ISSN:1949-2553
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Idelalisib is a targeted agent that potently inhibits PI3Kδ which is exclusively expressed in hematological cells. Bendamustine is a well-tolerated cytotoxic alkylating agent which has been extensively used for treatment of chronic lymphocytic leukemia (CLL). Both these agents are FDA-approved for CLL. To increase the potency of idelalisib and bendamustine, we tested their combination in primary CLL lymphocytes. While each compound alone produced a moderate response, combination at several concentrations resulted in synergistic cytotoxicity. Idelalisib enhanced the bendamustine-mediated DNA damage/repair response, indicated by the phosphorylation of ATM, Chk2, and p53. Each drug alone activated γH2AX but combination treatment further increased the expression of this DNA damage marker. Compared with the control, idelalisib treatment decreased global RNA synthesis, resulting in a decline of early-response and short-lived MCL1 transcripts. In concert, there was a decline in total Mcl-1 protein in CLL lymphocytes. Isogenic mouse embryonic fibroblasts lacking MCL1 had higher sensitivity to bendamustine alone or in combination compared to MCL1 proficient cells. Collectively, these data indicate that bendamustine and idelalisib combination therapy should be investigated for treating patients with CLL.
[Mh] Termos MeSH primário: Cloridrato de Bendamustina/farmacologia
Dano ao DNA
Purinas/farmacologia
Quinazolinonas/farmacologia
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/farmacologia
Linhagem Celular
Sobrevivência Celular/efeitos dos fármacos
Sobrevivência Celular/genética
Células Cultivadas
Relação Dose-Resposta a Droga
Sinergismo Farmacológico
Embrião de Mamíferos/citologia
Fibroblastos/citologia
Fibroblastos/efeitos dos fármacos
Fibroblastos/metabolismo
Regulação Leucêmica da Expressão Gênica/efeitos dos fármacos
Seres Humanos
Immunoblotting
Leucemia Linfocítica Crônica de Células B/genética
Leucemia Linfocítica Crônica de Células B/metabolismo
Leucemia Linfocítica Crônica de Células B/patologia
Camundongos Knockout
Proteína de Sequência 1 de Leucemia de Células Mieloides/genética
Proteína de Sequência 1 de Leucemia de Células Mieloides/metabolismo
Proteínas Proto-Oncogênicas c-bcl-2/genética
Proteínas Proto-Oncogênicas c-bcl-2/metabolismo
Reação em Cadeia da Polimerase Via Transcriptase Reversa
Células Tumorais Cultivadas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (MCL1 protein, human); 0 (Myeloid Cell Leukemia Sequence 1 Protein); 0 (Proto-Oncogene Proteins c-bcl-2); 0 (Purines); 0 (Quinazolinones); 981Y8SX18M (Bendamustine Hydrochloride); YG57I8T5M0 (idelalisib)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170707
[Lr] Data última revisão:
170707
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170211
[St] Status:MEDLINE
[do] DOI:10.18632/oncotarget.15180


  10 / 571 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28169430
[Au] Autor:Berdeja JG; Bauer T; Arrowsmith E; Essell J; Murphy P; Reeves JA; Boccia RV; Donnellan W; Flinn I
[Ad] Endereço:Sarah Cannon Research Institute, Nashville, TN, USA.
[Ti] Título:Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy.
[So] Source:Br J Haematol;177(2):254-262, 2017 Apr.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The combination of bendamustine, bortezomib and dexamethasone (BBD) was evaluated as a first-line therapy for multiple myeloma. The original treatment regimen of bendamustine 80 mg/m , days 1, 4; bortezomib 1·3 mg/m , days 1, 4, 8, 11; dexamethasone 40 mg, days 1, 2, 3, 4 on a 28-day cycle (up to 8 cycles) was efficacious but determined relatively toxic in an interim analysis. The regimen was amended to bendamustine 80 mg/m , days 1, 2; bortezomib 1·3 mg/m , days 1, 8, 15; dexamethasone 20 mg, days 1, 2, 8, 9, 15, 16 every 28 days (up to 8 cycles), then maintenance 1·3 mg/m IV bortezomib every 2 weeks. Fifty-nine patients were enrolled. Primary endpoint was complete response (CR) rate. The original schema was given for a median of 7 cycles (range 1-8); modified schema was given for a median of 8 cycles (range 1-8) plus maintenance. Overall response was 91%, CR was 9%. Median follow-up was 19·1 months; median progression-free survival was 11·1 months and 18·9 months on the original and modified regimens, respectively. The most common Grade 3/4 adverse events were fatigue and neuropathy. The combination of BBD is tolerable and efficacious in this patient population. Modifications to decrease intensity but increase duration translated to better outcomes.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Mieloma Múltiplo/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Cloridrato de Bendamustina/administração & dosagem
Bortezomib/administração & dosagem
Dexametasona/administração & dosagem
Relação Dose-Resposta a Droga
Feminino
Seres Humanos
Masculino
Meia-Idade
Mieloma Múltiplo/patologia
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
69G8BD63PP (Bortezomib); 7S5I7G3JQL (Dexamethasone); 981Y8SX18M (Bendamustine Hydrochloride)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170614
[Lr] Data última revisão:
170614
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170208
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.14536



página 1 de 58 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde